Interview with Selwyn Kahanovitz, CEO, Litha Healthcare Group Limited
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
Ferring is a speciality, research-driven biopharmaceutical company that identifies, develops, manufactures and markets innovative products in the fields of reproductive health, urology, gastroenterology and endocrinology.
From its origins as a distinctly Scandinavian company, Ferring has developed into a global business with operating units in most important pharmaceutical markets around the world.
Ferring (Pty) Ltd established operations in South Africa in 1996 with a limited portfolio of products. The company has now expanded its activities into a number of other countries within the region including Namibia, Botswana, Kenya and Mauritius. The portfolio of products has grown to include a range of products in the fields of urology, gastroenterology, obstetrics, gynaecology and infertility treatment.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
Ferring’s vision is to be the partner of choice for patients, physicians and business associates offering a leading portfolio of products and services in its key therapeutic areas, using innovative methodologies to provide tailored treatments that function on the body’s own terms.
Contact Details
Route 21 Corporate Park
6 Regency Drive
Irene Ext 30
Gauteng, South Africa
Mr Kahanovitz, Focus Reports came to South Africa in 2005 to produce a similar report on the South African pharmaceutical industry. Could you come back for us on the main…
The story of Novo Nordisk South Africa began in 1959 in Johannesburg. It was among the first affiliates outside of Denmark, with insulin and anti-infectives produced locally. To what extent…
You have worked at Roche for several years as Business unit Manager. Therefore you are familiar with the strategy of the company and the intricacies of the job. The new…
Having spent two months as the head of Novartis South Africa, what is your first assignment as General Manager, could you share with our readers what were the surprises for…
Mr. Miller, you have been Vice President and Managing Director of Mylan’s operations in South Africa since 2008. What mission were you assigned back then, and in those three years,…
South Africa carries one of the world’s most disproportionate disease burdens, the worst of so-called westernised diseases, such as cardiac disease, diabetes etc on the one hand and the developmental…
Mr Norman, could you tell us a few words on the transformation process that the company is currently going through? Takeda acquired Nycomed in October 2011, because it was an…
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Focus Reports is back in South Africa as part of a second set of reports on the BRICS. What would you say are the main changes in the market since…
South Africa is at the moment one of the world’s most exciting and dynamic markets at the moment as Mr. Omar Ehsan was telling us, the most exciting market he…
Could you introduce to our readers MC Pharma’s business model in the South African market as well as the main milestones in the company’s development over the recent years? MC…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
See our Cookie Privacy Policy Here
